*25% of their data with there first study went missing.
*Not one director has ever brought a single share on market paying full price in the last 5 years.
* 2 people saw a 80% reduction in AHI... 2 persons is not a cure. This was a crossover study because they could not get enough participants. Cross over studies are not the Gold standard.
* The open label extension study was abandoned after no one wanted to complete it..That news has not been updated to the market yet.
* Their patents are Method, packaging and Distribution of a drug patents....Not actual drug patents.
* Full report is still to be made publically available on there trial that was completed 7 months ago.
